Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients

NCT02278276 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: sodium polysulthionate
DRUG: Placebo

Sponsor

Sulfagenix Australia Pty Ltd.